Juvenile Dermatomyositis (JDM)

What happens in juvenile dermatomyositis

In JDM, the immune system attacks the small blood vessels (capillaries) that feed the skin and muscles. Inflamed, damaged vessels reduce blood flow, so muscle fibers weaken and the skin develops characteristic rashes. The trigger is unknown. Genetic susceptibility combined with an environmental trigger, such as an infection or sun exposure, is thought to start it. It is not contagious and not caused by anything the parents did.

JDM differs from adult dermatomyositis in important ways: it is rarely linked to cancer, calcium deposits in the skin are more common, and blood vessel involvement is more prominent.

Symptoms

Symptoms usually build over weeks to months. Many children are first thought to have eczema, a virus or "growing pains".

Skin signs

• Heliotrope rash: a purple or violet discoloration of the upper eyelids, often with puffiness
• Gottron papules: red or purple, slightly raised, scaly bumps over the knuckles, elbows and knees
• redness of the cheeks and nose, the V of the neck and the upper back
• enlarged, twisted blood vessels and redness at the nail folds
• rash that worsens with sun exposure
• skin ulcers in more severe disease

Muscle signs

Muscle weakness mainly affects the large muscles near the trunk: hips, thighs, shoulders, neck and belly.

• difficulty climbing stairs, getting up from the floor (using hands to "climb up" the legs, called Gowers sign) or getting into a car
• trouble lifting the head off the pillow, brushing hair or holding arms up
• frequent falls, tiring easily, wanting to be carried
• muscle pain and tenderness
• difficulty swallowing or a hoarse, nasal voice when throat muscles are affected

Other symptoms

Fever, tiredness, irritability, weight loss, joint pain and swelling, belly pain and, less often, breathing problems.

Calcinosis

Calcinosis means hard deposits of calcium under the skin or in muscles, often over elbows, knees and buttocks. They can be painful, break through the skin and drain chalky material, and limit movement. Calcinosis develops in a significant minority of children, more often when treatment is delayed or disease stays active. It is linked to the anti-NXP2 antibody. Early, effective treatment is the best prevention. See calcinosis.

Diagnosis

A pediatric rheumatologist makes the diagnosis from the rash, the pattern of weakness and supporting tests:

1. Blood tests: muscle enzymes (CK, aldolase, LDH, AST, ALT). These can be normal even with active disease.
2. Myositis-specific antibodies: such as anti-NXP2, anti-TIF1-gamma and anti-MDA5. They help predict features like calcinosis or lung disease.
3. MRI of the thighs: shows muscle inflammation without needles, and is the preferred first imaging test.
4. Nailfold capillaroscopy: a magnified look at the tiny vessels at the base of the nails.
5. Muscle biopsy: confirms the diagnosis when the picture is unclear.
6. Swallow study, lung function tests and heart checks when symptoms suggest involvement.

Conditions that can look similar include muscular dystrophies, viral myositis, lupus and other overlap syndromes.

Treatment

The aim is to control inflammation quickly to prevent muscle damage and calcinosis.

• Corticosteroids: high doses, often given first as IV pulses (methylprednisolone) and then as daily prednisone tapered over months.
• Methotrexate: a weekly medicine started at diagnosis. It allows steroid doses to be reduced and is the standard partner drug.
• Intravenous immunoglobulin (IVIG): for more severe or resistant disease and for skin disease.
• Other options: hydroxychloroquine for skin, mycophenolate, rituximab, cyclophosphamide for severe disease, and JAK inhibitors in refractory cases.
• Sun protection: broad-spectrum sunscreen of SPF 30 or higher, hats and protective clothing, because UV light worsens the rash and can trigger flares.
• Physical and occupational therapy: to rebuild strength, prevent joint contractures and support schoolwork and play.
• Supporting bones: calcium and vitamin D, and bone density monitoring, because long steroid courses weaken bones.

Children on immune-suppressing medicines should avoid live vaccines and need prompt care for fever. Inactivated vaccines, including flu, are recommended.

Complications

• calcinosis
• joint contractures and muscle wasting
• swallowing problems and aspiration pneumonia
• lung disease (interstitial lung disease), especially with anti-MDA5 antibodies
• gut wall inflammation, which rarely causes bleeding or perforation
• lipodystrophy (loss of body fat) and insulin resistance
• side effects of long-term steroids: weight gain, slowed growth, bone thinning, cataracts

Outlook

Courses vary. Some children have one episode that resolves within about 2 years (monocyclic), others have flares and remissions (polycyclic), and some have ongoing activity (chronic). About half reach remission off medicine. With modern treatment, deaths from JDM are rare, and most children return to school, sport and normal activities. Regular follow-up continues for years because flares and late complications can occur.

Frequently asked questions

What are the first signs of juvenile dermatomyositis?

Often a purple rash on the upper eyelids or red, scaly bumps over the knuckles, along with tiredness, irritability and gradually increasing weakness. Parents may notice the child struggling on stairs, falling more, or asking to be carried. The rash can appear weeks before the weakness.

Is juvenile dermatomyositis life-threatening?

It can be serious if muscles used for swallowing or breathing are affected, or if the gut or lungs are involved, but with modern treatment deaths are rare. Prompt diagnosis and early, adequate treatment are the most important factors in a good outcome.

Is juvenile dermatomyositis linked to cancer?

Unlike adult dermatomyositis, JDM is very rarely associated with cancer. Doctors may still perform some checks if features are unusual, but routine extensive cancer screening is generally not needed in children.

How long does treatment for JDM last?

Usually at least 2 years. Steroids are tapered over months as the disease comes under control, and methotrexate is often continued for a year or more after remission before being slowly stopped. Children with persistent disease may need longer treatment.

Can children with JDM go to school and play sport?

Yes. Once the disease is controlled, most children attend school normally and are encouraged to stay active, guided by their physical therapist. Sun protection outdoors, extra time between classes during flares and avoiding infection exposures on strong immune-suppressing medicines help.